Orchard Therapeutics has revealed its US pricing plans for Lenmeldy, its gene therapy for metachromatic leukodystrophy (MLD), placing a $4.25 million price tag on the one-shot treatment.
The therapy, Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel), is already approved in the UK and some other European countries, where it is known as Libmeldy. Orchard Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback